![David Shin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David Shin
Geschäftsführer bei
Limelight Bio, Inc.
Profil
David Shin is currently the Chief Operating Officer at Limelight Bio, Inc. He is also a Venture Partner & CSO at SRI Capital Partners LLC and Sri Capital.
Previously, he held positions as the Director of Technology at Thermo Fisher Scientific, Inc. from 2004 to 2007, Senior Director at Clearview Projects, Inc. in 2008, Vice President at Cascadian Therapeutics LLC from 2014 to 2016, and Vice President at Alpine Biosciences, Inc. in 2014.
He also worked as a Senior Analyst at Ayer Capital Management LP.
Dr. Shin received his undergraduate degree from Carnegie Mellon University in 1993 and his doctorate degree from the University of Pennsylvania in 1997.
Aktive Positionen von David Shin
| Unternehmen | Position | Beginn |
|---|---|---|
Limelight Bio, Inc.
 Limelight Bio, Inc. BiotechnologyHealth Technology Develops genetic therapies | Geschäftsführer | 01.09.2017 |
Sri Capital
 Sri Capital Investment ManagersFinance Sri Capital invests in companies located in the United States and India with revenue of at least USD 1 million. The firm focuses on artificial intelligence, robotics, enterprise software, digital health. It provides financing for early stage capital requirements with in investment size ranging from USD 0.5 to 2 million with meaningful minority interest. The firm acts as a lead investor and also makes co-investments. | Private Equity Investor | - |
The Biotechnology Greenhouse Corp. of Southeastern PA
 The Biotechnology Greenhouse Corp. of Southeastern PA Investment ManagersFinance BioAdvance invests in companies located in the United States. The firm focuses on medical devices, tools, health, IT and other platform technologies. It participates in equity capital requirements with an investment ranging from USD 0.5-15 millions. | Private Equity Investor | 01.12.2023 |
Ehemalige bekannte Positionen von David Shin
| Unternehmen | Position | Ende |
|---|---|---|
| CASCADIAN THERAPEUTICS INC (USA) | Corporate Officer/Principal | 01.05.2016 |
Alpine Biosciences, Inc.
 Alpine Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development of protocells for treatment of rare diseases and cancer | Corporate Officer/Principal | 01.08.2014 |
Clearview Projects, Inc. | Corporate Officer/Principal | 01.03.2008 |
| THERMO FISHER SCIENTIFIC, INC. | Corporate Officer/Principal | 31.12.2006 |
Ayer Capital Management LP
 Ayer Capital Management LP Investment ManagersFinance Ayer Capital Management manages a global healthcare long/short equity hedge fund. The firm invests across all market-caps and maintains a very high turnover rate | Analyst-Equity | - |
Ausbildung von David Shin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
94
Beziehungen ersten Grades
10
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 10 |
|---|---|
Carnegie Mellon University
 Carnegie Mellon University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Cascadian Therapeutics LLC
 Cascadian Therapeutics LLC Medical SpecialtiesHealth Technology Develops therapeutic products for the treatment of cancer | Health Technology |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Biotechnology Greenhouse Corp. of Southeastern PA
The Biotechnology Greenhouse Corp. of Southeastern PA Investment ManagersFinance BioAdvance invests in companies located in the United States. The firm focuses on medical devices, tools, health, IT and other platform technologies. It participates in equity capital requirements with an investment ranging from USD 0.5-15 millions. | Finance |
Thermo Fisher Scientific, Inc.
 Thermo Fisher Scientific, Inc. Medical SpecialtiesHealth Technology Develops, manufactures and markets analytical and environment monitoring instruments | Health Technology |
Clearview Projects, Inc. | |
Ayer Capital Management LP
Ayer Capital Management LP Investment ManagersFinance Ayer Capital Management manages a global healthcare long/short equity hedge fund. The firm invests across all market-caps and maintains a very high turnover rate | Finance |
Sri Capital
Sri Capital Investment ManagersFinance Sri Capital invests in companies located in the United States and India with revenue of at least USD 1 million. The firm focuses on artificial intelligence, robotics, enterprise software, digital health. It provides financing for early stage capital requirements with in investment size ranging from USD 0.5 to 2 million with meaningful minority interest. The firm acts as a lead investor and also makes co-investments. | Finance |
Alpine Biosciences, Inc.
Alpine Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Provides research and development of protocells for treatment of rare diseases and cancer | Commercial Services |
Limelight Bio, Inc.
Limelight Bio, Inc. BiotechnologyHealth Technology Develops genetic therapies | Health Technology |
